Kim SC - Search Results

Year	Number of Results
1963	1
1965	1
1968	1
1970	1
1971	2
1972	4
1973	2
1974	3
1975	4
1976	2
1978	1
1979	4
1980	2
1981	1
1982	1
1983	2
1984	2
1985	1
1986	3
1987	1
1988	9
1989	5
1990	7
1991	7
1992	5
1993	7
1994	10
1995	11
1996	21
1997	23
1998	46
1999	29
2000	45
2001	33
2002	26
2003	46
2004	58
2005	70
2006	81
2007	93
2008	105
2009	86
2010	106
2011	135
2012	140
2013	166
2014	203
2015	188
2016	209
2017	207
2018	218
2019	244
2020	242
2021	264
2022	241
2023	216
2024	82

1

An Exosome-based Transcriptomic Signature for Noninvasive, Early Detection of Patients With Pancreatic Ductal Adenocarcinoma: A Multicenter Cohort Study.

Nakamura K, Zhu Z, Roy S, Jun E, Han H, Munoz RM, Nishiwada S, Sharma G, Cridebring D, Zenhausern F, Kim S, Roe DJ, Darabi S, Han IW, Evans DB, Yamada S, Demeure MJ, Becerra C, Celinski SA, Borazanci E, Tsai S, Kodera Y, Park JO, Bolton JS, Wang X, Kim SC, Von Hoff D, Goel A. Nakamura K, et al. Among authors: kim sc. Gastroenterology. 2022 Nov;163(5):1252-1266.e2. doi: 10.1053/j.gastro.2022.06.090. Epub 2022 Jul 16. Gastroenterology. 2022. PMID: 35850192 Free PMC article.

2

Comparing Effectiveness and Safety of SGLT2 Inhibitors vs DPP-4 Inhibitors in Patients With Type 2 Diabetes and Varying Baseline HbA1c Levels.

D'Andrea E, Wexler DJ, Kim SC, Paik JM, Alt E, Patorno E. D'Andrea E, et al. Among authors: kim sc. JAMA Intern Med. 2023 Mar 1;183(3):242-254. doi: 10.1001/jamainternmed.2022.6664. JAMA Intern Med. 2023. PMID: 36745425 Free PMC article.

3

Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis.

Kaze AD, Zhuo M, Kim SC, Patorno E, Paik JM. Kaze AD, et al. Among authors: kim sc. Cardiovasc Diabetol. 2022 Mar 23;21(1):47. doi: 10.1186/s12933-022-01476-x. Cardiovasc Diabetol. 2022. PMID: 35321742 Free PMC article.

4

Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study.

Khosrow-Khavar F, Kim SC, Lee H, Lee SB, Desai RJ. Khosrow-Khavar F, et al. Among authors: kim sc. Ann Rheum Dis. 2022 Jun;81(6):798-804. doi: 10.1136/annrheumdis-2021-221915. Epub 2022 Jan 13. Ann Rheum Dis. 2022. PMID: 35027405 Free PMC article. Clinical Trial.

5

Synergistic therapeutic combination with a CAF inhibitor enhances CAR-NK-mediated cytotoxicity via reduction of CAF-released IL-6.

Lee YE, Go GY, Koh EY, Yoon HN, Seo M, Hong SM, Jeong JH, Kim JC, Cho D, Kim TS, Kim SC, Jun E, Jang M. Lee YE, et al. Among authors: kim sc. J Immunother Cancer. 2023 Feb;11(2):e006130. doi: 10.1136/jitc-2022-006130. J Immunother Cancer. 2023. PMID: 36849201 Free PMC article.

6

Sustainable work in anaesthesiology and intensive care medicine.

Bette B, Kim SC, Kruse P, Coburn M. Bette B, et al. Among authors: kim sc. Anasthesiol Intensivmed Notfallmed Schmerzther. 2022 Oct;57(10):647-654. doi: 10.1055/a-1683-2164. Epub 2022 Oct 13. Anasthesiol Intensivmed Notfallmed Schmerzther. 2022. PMID: 36228602 German.

7

Tofacitinib and Risk of Malignancy: Results From the Safety of Tofacitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA) Study.

Khosrow-Khavar F, Desai RJ, Lee H, Lee SB, Kim SC. Khosrow-Khavar F, et al. Among authors: kim sc. Arthritis Rheumatol. 2022 Oct;74(10):1648-1659. doi: 10.1002/art.42250. Epub 2022 Sep 1. Arthritis Rheumatol. 2022. PMID: 35643956 Free PMC article. Clinical Trial.

8

A Circulating Panel of circRNA Biomarkers for the Noninvasive and Early Detection of Pancreatic Ductal Adenocarcinoma.

Xu C, Jun E, Okugawa Y, Toiyama Y, Borazanci E, Bolton J, Taketomi A, Kim SC, Shang D, Von Hoff D, Zhang G, Goel A. Xu C, et al. Among authors: kim sc. Gastroenterology. 2024 Jan;166(1):178-190.e16. doi: 10.1053/j.gastro.2023.09.050. Epub 2023 Oct 14. Gastroenterology. 2024. PMID: 37839499

9

A circulating cell-free DNA methylation signature for the detection of hepatocellular carcinoma.

Kim SC, Kim DW, Cho EJ, Lee JY, Kim J, Kwon C, Kim-Ha J, Hong SK, Choi Y, Yi NJ, Lee KW, Suh KS, Kim W, Kim W, Kim H, Kim YJ, Yoon JH, Yu SJ, Kim YJ. Kim SC, et al. Mol Cancer. 2023 Oct 6;22(1):164. doi: 10.1186/s12943-023-01872-1. Mol Cancer. 2023. PMID: 37803338 Free PMC article.

10

Combination of metformin/efavirenz/fluoxetine exhibits profound anticancer activity via a cancer cell-specific ROS amplification.

Kang BG, Shende M, Inci G, Park SH, Jung JS, Kim SB, Kim JH, Mo YW, Seo JH, Feng JH, Kim SC, Lim SS, Suh HW, Lee JY. Kang BG, et al. Among authors: kim sc. Cancer Biol Ther. 2023 Dec 31;24(1):20-32. doi: 10.1080/15384047.2022.2161803. Cancer Biol Ther. 2023. PMID: 36588385 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

3,315 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

3,315 results

Results by year